Rare blood clotting syndrome linked to COVID-19 vaccines explored in study

Publication date: Jul 09, 2025

Understanding how TTS occurs with or without proximate vaccine exposure is important to facilitate diagnosis and rapid treatment, and prevent serious consequences from this rare syndrome. Our findings not only clarify the risk factors for TTS but also offer pathways for better patient management in the future. “Unraveling the immune trigger behind VITT will give clinicians clear guidance to recognize and manage the rarebut increasingly reportedVITT-like clotting syndromes,” said Dr. Pip Nicolson, first author. “More information: Phillip LR Nicolson et al, Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: a comprehensive synopsis, Efficacy and Mechanism Evaluation (2025). “The consortium recommends the establishment of a national reference laboratory and registry to improve diagnosis and tracking of TTS cases. This article has been reviewed according to Science X’s editorial process and policies .

Semantics